Who backs Superluminal Medicines?
12 investors| Investor | Type | First invested |
|---|---|---|
| Insight Partners (New York) | PE / buyout | — |
| Gaingels | Venture capital | — |
| RA Capital Management | Asset manager | — |
| Evolution VC Partners | Venture capital | — |
| Nvidia | — | Sep 2026 |
| Catalio Capital Management | Venture capital | — |
| NVentures (Santa Clara) | Venture capital | — |
| Perceptive Advisors | Hedge fund | Sep 2026 |
| Deep Track Capital | Venture capital | Sep 2026 |
| INSight Partners | — | Sep 2026 |
| + 2 more investors · a free account shows the complete list | ||
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns
Membership and data by Private Market View
Superluminal Medicines investors
12 investors are on record for Superluminal Medicines, including Insight Partners (New York), Gaingels, RA Capital Management and Evolution VC Partners. By type, the record holds 5 venture capital firms, 1 hedge fund and 1 asset manager. The Series B in Sep 2026 drew 10 investors.
Free account
More of Superluminal Medicines with a free account
- ·The post-money valuation on its round
- ·The complete investor list: 12 names
- ·Watch Superluminal Medicines: the Monday email on marks, rounds and moves
For fundraisers
Work this list, don’t just read it
These 12 firms already write checks for companies like Superluminal Medicines in drug discovery. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.
Membership and data by Private Market View